These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ambrisentan: a review of its use in pulmonary arterial hypertension. Rivera-Lebron BN; Risbano MG Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study. Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771 [TBL] [Abstract][Full Text] [Related]
6. Role of ambrisentan in the management of pulmonary hypertension. Hrometz SL; Shields KM Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622 [TBL] [Abstract][Full Text] [Related]
7. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension. Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360 [TBL] [Abstract][Full Text] [Related]
8. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Pan Z; Marra AM; Benjamin N; Eichstaedt CA; Blank N; Bossone E; Cittadini A; Coghlan G; Denton CP; Distler O; Egenlauf B; Fischer C; Harutyunova S; Xanthouli P; Lorenz HM; Grünig E Arthritis Res Ther; 2019 Oct; 21(1):217. PubMed ID: 31655622 [TBL] [Abstract][Full Text] [Related]
9. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539 [TBL] [Abstract][Full Text] [Related]
15. Effects of Emulsion Composition on Pulmonary Tobramycin Delivery During Antibacterial Perfluorocarbon Ventilation. Orizondo RA; Fabiilli ML; Morales MA; Cook KE J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):251-9. PubMed ID: 26741303 [TBL] [Abstract][Full Text] [Related]
16. Solnatide Demonstrates Profound Therapeutic Activity in a Rat Model of Pulmonary Edema Induced by Acute Hypobaric Hypoxia and Exercise. Zhou Q; Wang D; Liu Y; Yang X; Lucas R; Fischer B Chest; 2017 Mar; 151(3):658-667. PubMed ID: 27815150 [TBL] [Abstract][Full Text] [Related]
17. Inhibitors of hypoxic pulmonary vasoconstriction prevent high-altitude pulmonary edema in rats. Berg JT; Ramanathan S; Swenson ER Wilderness Environ Med; 2004; 15(1):32-7. PubMed ID: 15040504 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. Yoshida S; Shirato K; Shimamura R; Nakahara N; Iwase T; Nakajima H Curr Med Res Opin; 2011 Sep; 27(9):1827-34. PubMed ID: 21812736 [TBL] [Abstract][Full Text] [Related]
20. High-performance reoxygenation from PLGA-PEG/PFOB emulsions: a feedback relationship between ROS and HIF-1α. Wang J; Wang R; Li N; Shen X; Huang G; Zhu J; He D Int J Nanomedicine; 2018; 13():3027-3038. PubMed ID: 29861634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]